AstraZeneca’s Brilinta, which is a blood thinner, has received another boost lately after data suggested it could reduce the risk of cardiac arrest in certain patients by almost one-third.
During a phase 3 trial among patients who had suffered a myocardial infarction (MI) within two years, or who were within a year of stopping anti-platelet treatment with an ADP inhibitor, it was noted that the risk of cardiovascular death fell by 29 per cent if patients are given Brilinta for longer, Pharma File revealed.
A member of the steering committee for the PEGASUS-TIMI 54 trial which provided the new data commented that their findings do more than simply boost AstraZeneca’s Brilinta, but could be “potentially practice changing”.
Mikael Dellborg, Professor of cardiology at Gothenburg University, explained that the findings could be important because “while more than seven million people worldwide suffer a heart attack each year, we know that fewer than half receive adequate long-term treatment to reduce their risk of further CV events”.
With this new data coming to light and extending the use of Brilinta, AstraZeneca may want to look at its pharmaceutical brand strategy to make sure it’s doing everything possible to capitalise on this positive news.
The organisation has suffered a few setbacks in recent years, including within its oncology drugs, where an immunotherapy combination failed in its pipeline, Pharma Phorum revealed.
This latest study into Brilinta and its efficacy is due to be presented at the European Society of Cardiology meeting in Barcelona later this year.